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Abstract: Ketogenic diet (KD; high fat, low carb) is a standard treatment for obesity, neurological
diseases (e.g., refractory epilepsy) and a promising method for athletes to improve their endurance
performance. Therein, the level of ketosis must be regulated tightly to ensure an effective therapy.
Here, we introduce a compact and inexpensive breath sensor to monitor ketosis online and
non-invasively. The sensor consists of Si-doped WO3 nanoparticles that detect breath acetone
selectively with non-linear response characteristics in the relevant range of 1 to 66 ppm, as identified
by mass spectrometry. When tested on eleven subjects (five women and six men) undergoing a 36-h
KD based on the Johns Hopkins protocol, this sensor clearly recognizes the onset and progression
of ketosis. This is in good agreement to capillary blood β-hydroxybutyrate (BOHB) measurements.
Despite similar dieting conditions, strong inter-subject differences in ketosis dynamics were observed
and correctly identified by the sensor. These even included breath acetone patterns that could be
linked to low tolerance to that diet. As a result, this portable breath sensor represents an easily
applicable and reliable technology to monitor KD, possibly during medical treatment of epilepsy and
weight loss.
Keywords: chemical sensor; breath analysis; semiconductor; nanotechnology; flame spray pyrolysis;
point-of-care; biomedical
1. Introduction
Ketogenic diet (KD, high fat at low carbohydrate and low protein intake) is a proven medical
treatment of refractory epilepsy (i.e., drug-resistant) [1] occurring in ~30% of the approx. 50 million
epileptics worldwide [2]. Also, it is an effective therapy for weight loss [3] with growing interest for
treating obesity-associated metabolic disorders [4] (e.g., diabetes [5] or fatty liver disease [6]), it acts
anti-inflammatory [7] and is even beneficial for athletes to improve their endurance performance
by altering fuel preference [8]. During KD, body energy consumption shifts from glucose as
primary fuel to the production and use of ketone bodies [9] while only moderate protein intake
should limit gluconeogenesis from amino acids [10]. In specific, acetoacetate (AcAc) is such
a ketone body formed in the hepatic mitochondria after β-oxidation of fatty acids and further
biochemical transformations (Figure 1a, box) [9]. Its rate of production is determined also by
the availability of mitochondrial 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) synthase
induced by fasting, cyclic adenosine monophosphate (cAMP) and fatty acids [11]. Other ketones
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are β-hydroxybutyrate (BOHB) and volatile acetone obtained from AcAc by reversible enzymatic
degradation and spontaneous decarboxylation, respectively [9].
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Figure 1. (a) Participants undergoing a KD feature intensified ketogenesis. Therein, acetone and 
BOHB are formed at elevated rates by metabolizing free fatty acids in the hepatic mitochondria (box). 
Acetone is volatile and can be measured non-invasively in the exhaled breath while non-volatile 
BOHB can be determined through capillary blood assay. To indicate the status of ketosis, breath 
acetone is measured with tailor-made and inexpensive chemoresistive sensing films (b). These consist 
of agglomerated and aggregated Si-doped WO3 nanoparticles, as indicated by SEM (top view). Sensor 
results are compared to parallel measurements of breath acetone by QMS and capillary blood BOHB. 
(c) Experimental protocol: Volunteers ingest a total of 8 ketogenic meals every 3 h (circles) on two 
consecutive days. Breath and capillary blood are analyzed 10 times, always just before the ketogenic 
meals and at the end of each measurement day. Prior to and in between both days, overnight fasting 
(gray shaded) is performed. 
During a KD, frequent monitoring is desired to assure the persistence of the ketogenic state. 
Currently, this is done primarily by measuring AcAc or BOHB in urine or blood [12]. Despite blood 
assay’s accuracy, it is not ideal for frequent monitoring due to its invasiveness and cost. The urine 
assay also has drawbacks, in particular, its low precision due to varying factors such as patients’ 
hydration and acid-base balance [13]. Exhaled acetone measurement is a promising alternative, with 
breath being always accessible in a non-invasive manner [14]. In fact, measurements on 12 healthy 
adults revealed increasing breath acetone levels from average 0.7 to 2.5 ppm after a 12-h KD 
correlating well with plasma BOHB and urinary AcAc [12], a similar trend as observed in other 
studies [15]. This is even more pronounced in epileptic children that may follow a KD for several 
months, reaching breath acetone concentrations >100 ppm [16]. Most importantly, all studies reported 
strong inter-subject differences in ketogenic profiles at the same dietary conditions [12,15,16] 
highlighting the need for frequent and individual monitoring to provide personalized feed-back. 
In general, the collection of repetitive measurements of biomarkers, their analysis and 
interpretation, serving as basis for individualized health recommendations, is considered as one of 
the most promising tools of modern personalized medicine. Currently, only few such systems are 
clinically available, but these have been shown to be superior compared to traditional systems. An 
example is the continuous measurement of glucose in patients with diabetes with semi-automated 
systems guiding insulin therapy [17]. 
Figure 1. (a) Participants undergoing a KD feature intensified ketogenesis. Therein, acetone and
BOHB are formed at elevated rates by metabolizing free fatty acids in the hepatic mitochondria (box).
Acetone is volatile and can be measured non-invasively in the exhaled breath while non-volatile BOHB
can be determined through capillary blood assay. To indicate the status of ketosis, breath acetone
is measured with tailor-made and inexpensive chemoresistive sensing films (b). These consist
of agglomerated and aggregated Si-doped WO3 nanoparticles, as indicated by SEM (top view).
Sensor results are compared to parallel measurements of breath acetone by QMS and capillary blood
BOHB. (c) Experimental protocol: Volunteers ingest a total of 8 ketogenic meals every 3 h (circles) on
two consecutive days. Breath and capillary blood are analyzed 10 times, always just before the ketogenic
meals and at the end of each measurement day. Prior to and in between both days, overnight fasting
(gray shaded) is performed.
During a KD, frequent monitoring is desired to assure the persistence of the ketogenic state.
Currently, this is done primarily by measuring AcAc or BOHB in urine or blood [12]. Despite blood
assay’s accuracy, it is not ideal for frequent monitoring due to its invasiveness and cost. The urine assay
also has drawbacks, in particular, its low precision due to varying factors such as patients’ hydration
and acid-base balance [13]. Exhaled acetone measurement is a promising alternative, with breath
being always accessible in a non-invasive manner [14]. In fact, measurements on 12 healthy adults
revealed increasing breath acetone levels from average 0.7 to 2.5 ppm after a 12-h KD correlating well
with plasma BOHB and urinary AcAc [12], a similar trend as observed in other studies [15]. This is
even more pronounced in epileptic children that may follow a KD for several months, reaching breath
acetone concentrations >100 ppm [16]. Most importantly, all studies reported strong inter-subject
differences in ketogenic profiles at the same dietary conditions [12,15,16] highlighting the need for
frequent and individual monitoring to provide personalized feed-back.
In general, the collection of repetitive measurements of biomarkers, their analysis and
interpretation, serving as basis for individualized health recommendations, is considered as one
of the most promising tools of modern personalized medicine. Currently, only few such systems
are clinically available, but these have been shown to be superior compared to traditional systems.
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An example is the continuous measurement of glucose in patients with diabetes with semi-automated
systems guiding insulin therapy [17].
Despite their outstanding sensitivity and selectivity, applied mass spectrometry-based methods
(e.g., GC-FID [12,16], GC-MS [18], SIFT-MS [15]) are rather bulky, costly and require trained personnel
impeding their application as personal breath acetone detectors in daily life. More suitable are
chemical gas sensors, for instance, based on chemoresistive metal-oxides. They are applied already
in indoor air monitoring with typical costs per unit of few U.S. dollars (e.g., Figaro TGS 813 for
combustible gases [19]). This is enabled by scalable and CMOS compatible technologies for the
sensing film fabrication. Specifically, their sensing structure can be grown [20] or deposited (e.g.,
by thermophoresis from flame aerosols [21] or doctor-blading [22]) directly on micro-machined
chips resulting in compact sensors for ready integration into hand-held devices [23]. Furthermore,
their film morphology and deposited mass can be optimized during fabrication by in-situ resistance
read-out [24]. When nanostructured, such sensors exhibit high sensitivity to detect even low ppb
analyte concentrations [21]. Nevertheless, selectivity against other exhaled compounds that might
occur at higher concentrations remains a major challenge.
ε-phase WO3 nanoparticles are particularly suitable due to their outstanding selectivity
(e.g., to ethanol, methanol, NO, NO2, CO or NH3) [25] and high sensitivity to detect acetone down to
20 ppb even at breath-relevant 90% relative humidity (RH) [26]. This metastable phase can be stabilized
by Si- [27] or Cr-doping [25] during flame aerosol synthesis. Combined with an end-tidal breath
sampler [28], such sensors have been used already to monitor fat burn rates through breath acetone
online during exercise and rest in 20 volunteers in good agreement to state-of-the-art proton transfer
reaction time-of-flight mass spectrometry and venous blood BOHB [29]. Even sub-ppm concentrations
of breath- and skin-emitted acetone can be detected with high accuracy (i.e., 19 ppb) [30] when used in
combination with isoprene-selective Ti-doped ZnO [31] and ammonia-selective Si-doped MoO3 [32]
as an orthogonal sensor array for search and rescue applications. Note that isoprene is an attractive
breath marker for physical activity [33] and has potential for non-invasive cholesterol monitoring [34]
while breath ammonia could be applied to detect end-stage renal disease [35]. For KD monitoring,
however, selective detection of breath acetone at higher ppm concentrations [16] is necessary. So far,
Si-doped WO3 sensors had been characterized only up to 3 ppm at 90% RH in simulated breath [26]
and up to 2.4 ppm in real breath [29].
Here, compact sensors based on Si-doped WO3 nanoparticles are tested to monitor ketosis during
a 36-h ketogenic diet based on the Johns Hopkins protocol [36] (Figure 1). Together with a sampler for
end-tidal breath extraction [28], these sensors are applied on eleven volunteers (five females and six
males) to monitor their individual breath acetone profiles. Sensor responses are compared closely to
quadrupole mass spectrometry (QMS) to identify the sensing characteristics at elevated breath acetone
concentrations up to 66 ppm. Simultaneous capillary blood assay (BOHB and glucose) is performed as
a benchmark.
2. Materials and Methods
2.1. Acetone Sensor Fabrication and Film Characterization
The sensor is based on Si-doped WO3 nanoparticle films prepared by flame spray pyrolysis
(FSP) [26]. The precursor solution consisted of ammonium metatungstate hydrate (Sigma Aldrich,
St- Louis, MO, USA, purity≥97%) and hexamethyl disiloxane (Sigma Aldrich, purity≥98%) diluted in
a mixture of 1:1 ethanol (Sigma Aldrich, purity ≥99.8%) and diethylene glycol monobutyl ether (Sigma
Aldrich, purity ≥98%) to obtain a final metal (W and Si) concentration of 0.2 M at 10 mol% Si content.
This solution was fed through a capillary at 5 mL min−1 and dispersed by 5 L min−1 oxygen at a
pressure drop of 1.5 bar. A surrounding premixed methane (1.25 L min−1)/oxygen (3.2 L min−1) flame
was used to ignite the spray while 5 L min−1 sheath oxygen through an annulus surrounding the flame
ensured complete combustion. Obtained nanoparticles were deposited directly by thermophoresis [37]
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for 4 min at 20 cm height above the burner onto interdigitated Pt electrodes (sputtered, 350 µm width
and spacing) on Al2O3 substrates (15 mm × 13 mm × 0.8 mm, Electronic Design Center, Case Western
Reserve University, USA). Furthermore, adhesion and cohesion were increased by in-situ annealing
with a particle-free xylene-flame (11 mL min−1) for 30 s and an oxygen dispersion rate of 5 L min−1.
Finally, the sensors were thermally stabilized by annealing in an oven (Carbolite Gero 30–3000 ◦C) at
500 ◦C for 5 h. The sensing film’s morphology was evaluated with a Hitachi FE-SEM 4000 scanning
electron microscope (SEM) operated at 5 kV.
2.2. Breath and Blood Analysis
End-tidal breath was extracted in a monitored and reproducible fashion with a tailor-made
and modular sampler illustrated and described in detail elsewhere (Figure 1a in ref. [28]). In brief,
it consisted of an inlet to measure airway pressure and guide the exhalation flow by visual prompting
and an open-ended exhalation tube to capture and buffer end-tidal breath. Volunteers were asked to
exhale for 30 s through a disposable mouthpiece into the sampler while maintaining an airway pressure
of 980 Pa (corresponding to 50 mL s−1 exhalation flow), as recommended by the American Thoracic and
European Respiratory Societies for sampling of NO [38]. A CO2 (Capnostat 5, Respironics, Murrysville,
PA, USA) was used to check if the volunteer reached the end-tidal breath portion (CO2 > 3% [39]) at the
end of the exhalation. Breath was analyzed online by directing samples through a heated transfer line
to the acetone sensor and a mass spectrometer for cross-validation. All surfaces in contact with breath
consisted of inert Teflon and were heated (65 ◦C) to avoid water condensation and analyte adsorption.
The acetone sensor was mounted on a Macor holder, installed inside a Teflon chamber (shown
in Figure 1a of [40]) and fed with 130 mL min−1 from the sampler with a pump (SP 135 FZ,
Schwarzer Precision, Essen, Germany). For optimal selectivity and sensitivity, the acetone sensor was
heated to 350 ◦C [40] by applying constant voltage (R&S HMC8043, HAMEG, Mainhausen, Germany)
through a Pt heater located on the backside of the substrates while monitoring the temperature with
a resistance temperature detector on the front. The resistance of the sensing film was continuously
measured and recorded by a Multimeter (Keithley 2700, Keithley Instruments, Solon, OH, USA).
The sensor response S was defined as [29]
S =
Rair
Rbreath
− 1, (1)
with Rair and Rbreath being the sensor resistances in background room air and upon breath
exposure, respectively.
An additional line was connected just before the acetone sensor chamber to extract samples for
the QMS (QMS 422, ThermoStarTM, Pfeiffer Vacuum, Asslar, Germany). Secondary electron multiplier
voltage was set to 950 V, while the analysis unit was heated to 150 ◦C. For acetone detection, the ion
current at mass-to-charge ratio of 58.0 was measured with a dwell time of 0.2 s and resolution of
200. The QMS was calibrated with 9-point curves of single-component acetone in the range of 0.5
to 50 ppm in synthetic air at 90% RH. Certified acetone cylinder gas (13.6 ppm in synthetic air, Pan
Gas, for concentrations ≤ 1 ppm and 500 ppm in synthetic air, Pan Gas, for concentrations > 1 ppm)
was diluted in humidified synthetic air (Pan Gas 6.0, CnHm and NOx ≤ 100 ppb) with a mixing setup
described elsewhere [32]. Capillary blood was sampled via finger pricking with lancet pens. BOHB and
glucose were determined with a FreeStyle Neo Precision (Abbott Diabetes Care, Alameda, CA, USA).
2.3. Study Protocol
Healthy non-smokers free from respiratory or cardiovascular disease were included in this study.
Each volunteer was informed about the experimental protocol prior to the test, gave written consent
and could interrupt the test or withdraw consent anytime. This study was approved by the local ethics
commission (Kantonale Ethikkommission Zürich, #2015-0675). Weight and height were measured on
the first day prior to the first experiment. The participants followed a fat:(carbohydrate+protein) 4:1
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KD based on the Johns Hopkins protocol [36] for 36 h including overnight fasting periods. The study
timeline is illustrated schematically in Figure 1c. Each subject was asked to avoid physical exercise and
alcoholic beverages 24 h before and during the experiment, fast for 12 h prior to the experiment and to
avoid tooth brushing and mouth wash 2 h prior to and during the experiment to minimize exogenous
confounders. Participants were allowed to drink water throughout the experiment but were asked to
stop 30 min before breath and blood sampling. On the first day, each volunteer was given a total of
4 liquid ketogenic meals (circles, Figure 1c) every 3 h starting at around 8 a.m. This was followed by
15 h of fasting during the night and another 4 ketogenic meals on the second day at the same times.
Breath and blood samples (diamonds, Figure 1c) were collected just before meal consumption and at
the end of each testing day.
Each ketogenic meal was composed of 35% fat whipping cream (Coop, Basel, Switzerland) and
chocolate-flavoured protein supplement powder (Sponsor Whey Protein 94, Wollerau, Switzerland) to
accomplish a total fat content of 80 wt%. The corresponding macronutritional composition of both
products is summarized in Table 1. Four meals accounted for 75% of the 24-h energy expenditure (24-EE
in kcal/d) of the individual’s daily calorie requirement determined by multiplying the resting energy
expenditure (REE) of each volunteer with the physical activity factor. The REE is calculated using
the revised Harris-Benedict formula [41] which provides a quite accurate estimate in non-overweight
subjects [42]. The physical activity factor is based on the physical activity during working and free
time [43].
Table 1. Macronutrient composition of ketogenic meals.
Macronutrient Whipping Cream [wt%] Protein Supplement Powder [wt%]
Fat 35 2
Carbohydrates 3 3.8
Protein 3 80
Calories [kcal/g] 3.37 3.65
3. Results and Discussion
3.1. Study Cohort
Eleven volunteers (five females and six males) with a median age (±SD) of 22.7 (±2.0) years
participated in this study. Their body mass index was 22.4 (±3.3) kg/m2. All volunteers had office jobs
and were rather inactive (volunteers #1-9), moderately (volunteer #11) and highly active (volunteer
#10) during their free time. Consequently, physical activity factors of 1.4, 1.5 and 1.6 were assumed,
respectively, following the literature [43]. Individual physiological parameters, physical activity factors
and calculated 24-EE are shown in Table 2.
Table 2. Demographic and anthropometric data as well as calculated energy expenditures of
the participants.
Volunteer
[-]
Gender
[-]
Age
[y]
Weight
[kg]
Height
[m]
BMI
[kg/m2]
Physical
Activity Factors
[-]
24-h Energy
Expenditure
[kcal/d]
1 f 21 58.0 1.59 22.94 1.4 1831
2 m 23 69.4 1.77 22.15 1.4 2352
3 m 22 72.0 1.80 22.22 1.4 2610
4 f 22 51.4 1.63 19.35 1.4 1753
5 m 22 51.8 1.78 16.35 1.4 1598
6 f 28 78.8 1.63 29.66 1.4 2234
7 f 25 74.1 1.71 25.34 1.4 2142
8 m 22 73.2 1.73 24.46 1.4 1807
9 m 22 74.5 1.80 22.99 1.4 2471
10 m 22 70.8 1.82 21.37 1.6 2786
11 f 21 59.4 1.72 20.08 1.5 2100
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3.2. Breath Acetone Sensor Design
The applied breath acetone sensor consisted of chemoresistive Si:WO3 nanoparticles with average
particle size (dBET) of 12 nm [26]. By depositing them directly from flame-aerosols onto sensor
substrates by thermophoresis [37], these nanoparticles agglomerate and aggregate to fine and porous
sensing networks, as revealed by top-view SEM (Figure 1b). The open and nanostructured film
morphology is advantageous for gas sensing as analytes (e.g., acetone) can access easily the sensing
structure and interact with its large specific surface area. This promotes fast response times and
high sensitivity to detect, for instance, 20 ppb of acetone at breath-relevant 90% RH in less than 60 s,
as demonstrated on laboratory gas mixtures [40].
Human breath contains more than 870 compounds [44]. High selectivity is therefore a
key requirement for a breath acetone sensor. This is addressed by employing the ferroelectric
ε-phase of WO3 featuring a monoclinic, similar to the widely applied γ-phase, but acentric crystal
configuration [45]. This metastable phase (stable below −40 ◦C [45]) can be stabilized at room and
sensor operational temperature (350 ◦C [40]) by Si- [26] or Cr- [25] doping. It has been proposed
that the outstanding selectivity of ε-WO3 is associated to its spontaneous electric dipole moment that
interacts with the strong dipole moment of acetone [25]. However, also other factors may contribute to
acetone selectivity, for instance, the orientation of exposed surface facets, as demonstrated with WO3
nanorods [46].
3.3. Sensor Performance and Calibration at Elevated Breath Acetone Concentrations
Si:WO3 sensor response and QMS-measured breath acetone concentrations from eleven volunteers
(105 breath samples) from the 36-h KD are shown in Figure 2. In general, the sensor resolves the
entire range from 1.1 to 66.4 ppm, a remarkable performance considering the sensor’s compact
and inexpensive design compared to that of the QMS. However, the acetone sensitivity (i.e., slope of
response curve) decreases with increasing breath acetone concentrations indicating non-linear response
characteristics. This is similar to other flame-made metal-oxide sensors (e.g., Pt:SnO2 with CO [37])
at such concentrations and in agreement with non-linear diffusion-reaction theory [47]. Accordingly,
the response S can be approximated with a power law [48]: S = A·cBace + K with cace being the breath
acetone concentration. Best fit (dashed line, R2 = 0.95) was obtained with a pre-factor A of 6.32,
exponent B of 0.26 and constant K of −5.98. This transfer function was used in the following to
determine breath acetone concentrations from sensor responses.
It is also worth discussing the observed spread between sensor and QMS (Figure 2). This may
be related to minor interference of the sensor by other gases than acetone. In fact, Si:WO3 shows
a smaller response, for instance, to ethanol [26] or isoprene [40] that are contained typically at
sub-ppm concentrations in sober and healthy breath [49,50]. Also the high relative humidity in
exhaled breath alters the sensor response to acetone [26]. To compensate for these, the Si:WO3 sensor
could be combined with other selective sensors (e.g., Ti-doped ZnO for isoprene [31], Si-doped MoO3
for ammonia [32] and commercial humidity sensors) in orthogonal arrays [30]. Such improved
accuracy is especially required when lower ppb concentrations of acetone need to be detected (e.g.,
in search and rescue when sniffing entrapped humans [30]) but less important in KD monitoring where
exhaled acetone concentrations are at elevated ppm levels (Figure 2). Also filters (e.g., microporous
membranes [51] for larger interfering molecules or adsorption packed beds [52]) or GC columns [53]
are quite effective to improve selectivity.
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during the KD were analyzed and compared to a commercial capillary blood BOHB and glucose 
monitoring system. Figure 3 shows the simultaneously measured profiles for (a) breath acetone, (b) 
capillary blood BOHB and (c) glucose of five representative volunteers during a 36-h KD. Data of all 
eleven volunteers are provided in Figure S1. For volunteer #3 (black diamonds), breath acetone 
almost tripled within the first 12 h, similar to other KD studies where an average increase by a factor 
of 3.5 was observed [12]. Most interestingly, the strongest increase was observed after 30 h when 
breath acetone concentrations exceeded 20 ppm, which should reflect advanced ketosis from 
intensified ketogenesis [9] (Figure 1a, box). This is significantly higher than observed, for instance, 
during exercise and post-exercise rest where breath acetone levels did not exceed 3 ppm [29]. 
Remarkably, capillary blood BOHB (Figure 3b) as an established marker for ketosis followed the same 
dynamic. In specific, nutritional ketosis (0.5–3 mM [54]) is entered after 9 h and mild ketosis (2–7 mM 
[55]) after 36 h of KD, the latter is needed for an efficient treatment of epilepsy [56]. This indicates 
that the present breath acetone sensor is suitable to monitor ketosis during KD and, most importantly, 
it operates non-invasively. 
Within the first 12 h, a similar breath acetone trend was observed also for volunteers #5 (red 
squares), #10 (orange stars) and #11 (blue triangles). However, #5 and #11 differed significantly 
afterwards. In particular, breath acetone concentrations of both increased strongly already during 
overnight fasting (t = 12–24 h). On the second day, further increase was observed for volunteer #5 
who reached breath acetone concentrations above 60 ppm after 33 h, while they leveled off for #11 at 
around 30 ppm. These breath acetone trends were in agreement with BOHB (Figure 3b) where 
volunteer #5 reached highest levels above 3 mM toward the end of the KD. It is also interesting to 
Figure 2. Scatter plot between the Si-doped 3 sensor responses and QMS-measured acetone
concentrations of 105 breath samples (11 volunteers). Power law fit is indicated as dashed line together
with the corresponding coefficient of determination (R2). Inset images show the sensor chip (top left)
and the QMS instrument (bottom right).
3.4. Monitoring Indiv dual Ketosis through Breath a
As a next step, the indivi ual sensor-measured breath ceton dynamics of the volunteers during
the KD were analyzed and compared to a commercial capillary blood BOHB and glucose monitoring
system. Figure 3 shows the simultaneously measured profiles for (a) breath acetone, (b) capillary blood
BOHB and (c) glucose of five representative volunteers during a 36-h KD. Data of all eleven volunteers
are provided in Figure S1. For volunteer #3 (black diamonds), breath acetone almost tripled within the
first 12 h, similar to other KD studies where an average increase by a factor of 3.5 was observed [12].
Most interestingly, the strongest increase was observed after 30 h when breath acetone concentrations
exceeded 20 ppm, which should reflect advanced ketosis from intensified ketogenesis [9] (Figure 1a,
box). This is significantly higher than observed, for instance, during exercise and post-exercise rest
where breath acetone levels did not exceed 3 ppm [29]. Remarkably, capillary blood BOHB (Figure 3b)
as an established marker for ketosis followed the same dynamic. In specific, nutritional ketosis
(0.5–3 mM [54]) is entered after 9 h and mild ketosis (2–7 mM [55]) after 36 h of KD, the latter is needed
for an efficient treatment of epilepsy [56]. This indicates that the present breath acetone sensor is
suitable to monitor ketosis during KD and, most importantly, it operates non-invasively.
Within the first 12 h, a similar breath acet tr s observed also for volunteers #5 (red
squares), #10 (orange stars) and #1 (blue trian l . owever, #5 and # 1 diff red significantly
afterwards. In particular, breath acetone c i s of both increased strongly already during
overnight fasting (t = 12– 4 h). On the s cond ay, further increase was observed for volunteer #5 who
reac ed breath ac tone oncentratio s b ve 60 ppm after 33 h, while they lev led off for #11 at around
30 ppm. These breat acetone trends were i agreeme t with BOHB (Figure 3b) where volunteer #5
reached highest levels above 3 mM toward the end of the KD. It is also interesting to observe that
BOHB increased stronger than the breath acetone levels within the first 12 h for volunteer #11 and
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especially #5. This may be related to the dynamic equilibrium between BOHB and AcAc (Figure 1a,
box) [9]. In summary, the volunteers showed distinctly different ketosis dynamics despite similar KD
conditions, as recognized correctly by the sensor.
Finally, it is worth discussing volunteer #1 (Figure 3a, green circles) who showed a distinctly
different breath acetone profile. Most notably, this volunteer had already an extraordinary increase in
breath acetone at the beginning of the KD reaching about 60 ppm after 12 h. A similar trend within
the first 6 h is observed for blood BOHB (Figure 3b), though less distinct from the other volunteers
(e.g., #5, red squares) than observed for breath acetone (Figure 3a). Interestingly, BOHB decreases
thereafter. Glucose concentrations (Figure 3c, green circles), on the other hand, decreased until t = 6 h
and started to increase slightly thereafter coinciding with the drop in BOHB levels. On the second day,
this volunteer had to stop the KD due to strong nausea. This is probably caused by ketones activating
the chemoreceptor zone in the vomiting center of the brain that is a known reason for nausea and
vomiting in ketosis [57]. As a result, this volunteer showed low tolerance to the KD protocol that was
reflected in an abnormal breath acetone pattern. In a next step, the present breath acetone sensor could
be used to guide this volunteer to an optimized KD protocol (e.g., different nutritional composition) to
achieve and maintain a healthy status of ketosis.
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Corresponding capillary glucose levels (Figure 3c) of the five volunteers (for all volunteers,
see Figure S1c) were consistently below 5.5 mM at the start and during the KD. This suggests that they
adhered to the overnight fasting prior to the KD and stayed abstinent from other external carbohydrate
sources during the KD (see Figure 1c for protocol). During the KD, glucose levels typically decreased
within the first 12 h and leveled off thereafter between 3 and 5 mM probably due to gluconeogenesis
to inhibit hypoglycemia [10], as suggested above.
3.5. Correlations between Breath and Blood Parameters
The blood and breath ketone concentrations for all volunteers are shown in Figure 3d.
Breath acetone and capillary blood BOHB correlated significantly with Spearman’s rank correlation
coefficient ρ of 0.83 (p < 0.001) and Pearson’s correlation coefficient r of 0.78 (p < 0.001), as expected
from their similar intra-subject dynamics during KD (Figure 3a vs. Figure 3b) and joint biochemical
origin as products of ketogenesis (Figure 1a, box) [9]. When applying a power law fit (dashed line),
a degree of determination (R2) of 0.62 is obtained that is well within the range of fasting and dieting
experiments (0.54 ≤ R2 ≤ 0.94) [14].
A weaker and inverse correlation was found between breath acetone and capillary blood glucose
(r = −0.63, ρ = −0.59, both p < 0.001). This was anticipated from the observed trends during KD
(Figure 3a vs. Figure 3c). Ketogenesis is driven by hepatic β-oxidation which increases during fasting
when lipolysis increases as no longer suppressed by insulin and by the expression of mitochondrial
HMG-CoA synthase which is induced by fasting and downregulated by insulin [11]. Although low
insulin and high glucagon levels resulting from low blood glucose serve as an initial trigger for
ketogenesis, ketone body levels are rather determined by glucose level-independent effects, such as
free fatty acid availability for ketone body production and ketone body consumption by peripheral
tissues [58].
4. Conclusions
A compact and inexpensive breath acetone sensor was introduced to monitor the status of ketosis
during ketogenic diets. Its sensing film consisted of chemoresistive Si-doped WO3 nanoparticles that
showed high selectivity and non-linear response characteristics for breath acetone concentrations up to
around 66 ppm, as revealed by mass spectrometry. When applied on eleven volunteers during a 36-h
ketogenic diet, the breath sensor accurately followed the individual breath acetone dynamics, in general
agreement with capillary blood BOHB. Most interestingly, strong differences in individual breath and
blood profiles were identified between volunteers despite identical KD conditions. These were correctly
recognized by the breath acetone sensor including patterns possibly associated to low tolerance to
the KD protocol. The sensor’s ability to accurately and rapidly monitor individual changes in the
ketogenic state together with its compact size renders it attractive for repetitive measurements by
the public. As a result, this breath sensor is promising as a portable ketosis monitor in a broad range
of applications including personalized, non-pharmaceutical treatment of epileptics and guiding of
dietary interventions for weight loss.
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